Pyrilutamide Phase 3 on its way

    Treatment 11/24/2021
    Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
    View this post in the Community →

    Similar Community Posts Join

    6 / 727 results

    Related Research

    6 / 8 results